16:27 EDT Corcept Therapeutics (CORT) raises FY26 revenue view to $950M-$1.05B, consensus $933.2M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Analyst Reiterates Buy on Corcept, Sees Upside with Unchanged $110 Target as Korlym Growth Set to Re-Accelerate and Lifyorli Ramps
- Is CORT a Buy, Before Earnings?
- Corcept Therapeutics presents final overall survival data from ROSELLA trial
- Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims
- Corcept Therapeutics presents data from Momentum trial at ACC 2026